Overview

Phase 3 Efficacy and Safety Study in Adults With ADHD Using CTx-1301.

Status:
Not yet recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate the efficacy and safety of CTx-1301 in adults with ADHD in a laboratory classroom setting.
Phase:
Phase 3
Details
Lead Sponsor:
Cingulate Therapeutics
Collaborator:
Rho, Inc.
Treatments:
Dexmethylphenidate Hydrochloride